Lilly is expected to file with the FDA in early 2027. The piece also covers trial weight loss near 30% and warnings about gray-market vials sold as research only.
Recap by typeshit. Full story at Clarin.com.
Dr Alo, a cardiologist, says he is following the cardiovascular data on these drugs closely and that it is shifting how heart disease is treated.
50:28
DOWNSIZED looks at why appetite and food noise can creep back late in the weekly cycle, and what that may say about whether a GLP-1 is still working.
Avi Roy points to trial data on drugs like Ozempic, including a 16-week study of 73 people where milkshake ratings barely changed despite reduced appetite.
Research presented at the anesthesiology meeting linked GLP-1 use with lower odds of heart attack and other heart problems. It shows an association, not proof of cause.
Dr Alo argues semaglutide's bigger story is heart protection, citing SELECT trial results showing fewer cardiovascular events in people without diabetes.
Her point: food industry habits and sedentary lifestyles that drove weight gain are still there, even as millions start these medications.
Loading…